April 24 (Reuters) - Amphastar Pharmaceuticals (AMPH.O) will buy Baqsimi from Eli Lilly and Co (LLY.N) in a deal worth up to $1.08 billion as it aims to boost its portfolio of low blood sugar drugs, the two companies said on Monday.
HANGZHOU, China and SAN FRANCISCO, Dec. 9, 2021 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic disease, today announced the completion of patient enrollment in its Phase 2 clinical trial of XW003 in type 2 diabetes patients in China. XW003 is a novel, long-lasting glucagon-like peptide-1 (GLP-1) peptide analog optimized for improved biological activity, cost-effective manufacturing, and once weekly dosing. It has been shown to be safe and well tolerated, and induced dose-dependent weight reductions in healthy volunteers in a Phase 1 clinical trial that was completed earlier this year in Australia.
SAN DIEGO, Oct. 25, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that preclinical data from a series of novel dual agonists of the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors will be presented at ObesityWeek 2021, the annual meeting of The Obesity Society. Results from studies in diet induced obese (DIO) mice will be featured in two poster presentations at the conference, which is being held virtually November 1-5, 2021.
The Arizona District Court ordered Lilly to pay the royalties to Tucson, AZ-based Research Corporation Technologies, per an opinion delivered Tuesday, stemming from a 1990 agreement involving materials used in manufacturing Lilly’s insulin products. Lilly had agreed to pay a 2% royalty on worldwide sales, and the exact amount of damages will be determined in a trial, Judge Scott Rash wrote.
Enforcement Report - Week of October 20, 2021
Days after it was revealed that Eli Lilly’s diabetes injection kit had been recalled after a report of a mixup of glucagon substance, Reuters has reported the kits were manufactured in the Indianapolis plant called out in a Form 483.
On Monday, further details emerged, as a Reuters report stated that the batch in question was manufactured at an Indiana facility that had previously been cited by U.S. health regulators for quality-control violations, including several pertaining to this product.
Eli Lilly & Co. Issues Voluntary Nationwide Recall of Glucagon Emergency Kit